Print
Email

Email

Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing

Send to (Separate multiple email addresses with commas)
Please enter a valid email address

Your email address
Please enter a valid email address

Message (Optional)

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Email

Your email has been sent.
Share
Share
Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing

Clicking a link will open a new window.
Default text size A
Larger text size A
Largest text size A

Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing

, MT Newswires - 4:28 PM ET 4/4/2025 Company News

04:28 PM EDT, 04/04/2025 (MT Newswires) -- Marianne De Backer, Director, Chief Executive Officer, on April 03, 2025, sold 79,712 shares in Vir Biotechnology ( VIR ) for $474,239. Following the Form 4 filing with the SEC, De Backer has control over a total of 822,623 common shares of the company, with 769,505 shares held directly and 53,118 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1706431/000162828025016800/xslF345X05/wk-form4_1743798213.xml

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

Vir Biotechnology Insider Sold Shares Worth $474,239, According to a Recent SEC Filing

Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.

Your e-mail has been sent.

Frontier Airlines scraps forecast as Trump's trade war hits travel

Reuters - 46 minutes ago
Frontier Airlines scraps forecast as Trump's trade war hits travel

Reuters - 49 minutes ago
Soccer-Amorim shrugs off Onana mistakes after Manchester Utd held to draw

Reuters - 6:40 PM ET 4/10/2025
UBS hires Evan Raine as head of media and telecom M&A for Americas

Reuters - 6:40 PM ET 4/10/2025
China's Country Garden reaches offshore debt restructuring deal with some creditors

Reuters - 6:34 PM ET 4/10/2025
Russia and US bring ballerina and tech smuggler back home in prisoner swap

Reuters - 6:05 PM ET 4/10/2025
Centene Unit Gets Nevada Medicaid Contract

MT Newswires - 6:00 PM ET 4/10/2025

Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research

These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.